



Clone JC2: CE/IVD-classified antibody for detection of p16^{INK4a}

Das p16^{INK4a} protein, also known as *Cyclin Dependent Kinase Inhibitor 2A*, was discovered in the early 1990s and has since been studied extensively for its ability to affect cell cycle progression at the transition from G1 to S phase [1]. The 16 kDa protein was described as a specific inhibitor of cyclin-dependent kinase 4 (*Cyclin Dependent Kinase 4*, CDK4) - the suffix INK4 stands for *Inhibitor of Cyclin Dependent Kinase 4*. Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) regulate the cell cycle at the end of G1 phase. During G1 phase, cyclin D levels in the cell increase, cyclin D binds to CDK4 and CDK6 and the resulting cyclin/CDK protein complexes phosphorylate the retinoblastoma protein (Rb). Phosphorylation inactivates the Rb protein and bound and thus inactive transcription factors of the E2F family are released and mediate the expression of a variety of proteins essential for cell cycle progression and DNA synthesis, such as cyclin E, cyclin A, and thymidine kinase [1,2]. p16^{INK4a} binds to CDK4 and/or CDK6 and inhibits the catalytic activity of the cyclin/CDK complexes. Rb remains inactive, binds and inhibits E2F, preventing the transition of cells into the S phase of the cell cycle and progression of cell proliferation. Numerous other functions have been described for p16^{INK4a} over time. For example, it mediates MDM2-dependent degradation of p53, suppresses the kinase activity of c-Jun N-terminal kinases (JNK), is involved in the regulation of AKT/Survivin signaling, and represses transcription of numerous genes, such

Product information

Beschreibung	Status	Form	Dilution	Amount	Art-No.
p16 ^{INK4a} Clone: JC2 Host: Mouse	CE/IVD	Ready-to-use	-	6 ml	MSG123
		Concentrate	1:50 - 1:100	0.5 ml	MSK123-05

The antibody, which is CE/IVD classified, is used for the localization of the p16^{INK4a} protein in tissue sections of formalin-fixed and paraffin-embedded tissue.

as Rb, TP53, VEGF (*vascular endothelial growth factor*), MMP-2 (*matrix metalloproteinase 2*) or NF-κB [3]. It is therefore not surprising that p16^{INK4a} plays a critical role in key processes such as cell cycle, senescence and apoptosis.

p16^{INK4a} is encoded by the *CDKN2A* gene. *CDKN2A* is one of the most studied tumor suppressor genes. Mutations, DNA methylation, and homozygous or heterozygous gene loss can affect *CDKN2A* gene expression. Post-translational modifications modulate functionality and activity of the protein. A reduction in activity to complete inactivation of the tumor suppressor p16^{INK4a} involved in the regulation of G1 phase represents a frequent and early event in the pathogenesis of solid tumors [4,5]. However, while in these tumors the p16^{INK4a} protein is partly absent, or the expression level can be very diverse, in HPV-induced carcinomas there is an overexpression in the tumor cells [6]. The previously described complex of Rb and the transcription factor E2F, among others, also inhibits the transcription of the *CDKN2A* gene and thus the expression of p16^{INK4a}.

When the viral oncoprotein E7 is expressed as a result of HPV infection, it binds and inactivates the Rb protein. E2F transcription factors are released, p16^{INK4a} is expressed and accumulates in the cell, and yet the cell continues unhindered through the cell cycle [5,7].

The antibody has been intensively tested in ZytoMed Systems' own as well as in independent pathology laboratories using different manual and automated methods and protocols.



p16^{INK4a} detection at cervical intraepithelial neoplasia CIN3 (Mouse anti-p16^{INK4a} clone JC2, MSK123-05, 1:50; EDTA pH 9.0; ZytoChem Plus (HRP) Polymer Kit, POLHRP-100; DAB High Contrast, DABPLUS-5000)
©: ZytoMed Systems

Literatur

- [1] Serrano M *et al.* A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 366:704-707, 1993
- [2] Sherr CJ *et al.* D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. *Cold Spring Harb Symp Quant Biol* 59:11-19, 1994
- [3] Mirzayans R *et al.* Role of p16^{INK4A} in Replicative Senescence and DNA Damage-Induced Premature Senescence in p53-Deficient Human Cells. *Biochem Res Int* 2012:951574, 2012
- [4] Rocco JW & Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. *Experimental Cell Research* 264:42-55, 2001
- [5] Li J *et al.* The Regulatory Mechanisms of Tumor Suppressor P16INK4A and Relevance to Cancer. *Biochemistry* 50:5566-5582, 2011
- [6] Trunk MJ *et al.* Molekulare Pathogenese des Zervixkarzinoms und seiner Vorstufen. *Pathologe* 26:283-290, 2005
- [7] Lukas J *et al.* Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. *Nature* 375:503-506, 1995

For questions or requests regarding our full portfolio, write an email to international@zytomed-systems.de

Erfahren Sie mehr: www.zytomed-systems.de | Learn more: www.zytomed-systems.com